News & Scope Handai Hospital No. 75
Alleviating Pain and Distress of Patients and Families – Palliative Care Center Opens –
We treat all patients with hematological disorders, including hematopoietic malignant diseases such as leukemia, malignant lymphoma, myelodysplastic syndromes, and multiple myeloma, as well as anemia and hemostatic disorders. We are committed to providing the medical care services most appropriate for individual patients collaboratively with a team of physicians of various clinical sections, with respect for patient's rights, centering on the usual chemotherapy regimen, molecular target medication, radioimmunotherapy, and hematopoietic stem cell transplantation. We always strive to select the optimal treatment for individual cases based on the latest evidence. New examination techniques are used in daily consultation; moreover, clinical studies on new drugs are proactively conducted to provide up-to-date medical care services.
At present, about 200 patients, most of whom suffer from hematopoietic malignant diseases, are admitted annually. Among these inpatients, those with refractory disease and/or poor outcome undergo related bone marrow transplantation or unrelated hematopoietic stem cell transplantation with the assistance of the Japan Marrow Donor Program (JMDP). We also have abundant experience in the diagnosis and treatment of idiopathic thrombocytopenic purpura among hemorrhagic diseases, and accept a lot of patients referred from other medical facilities.
We actively treat patients with hematopoietic malignant diseases, mainly by chemotherapy and stem cell transplantation to achieve radical cure. Moreover, we make full use of advanced medical techniques, e.g., the surface marker test and gene diagnosis, and determine the treatment policy while monitoring the minimal residual disease using real-time PCR. Thrombasthenia and paroxysmal nocturnal hemoglobinuria are diagnosed by using a flow cytometer.
Allogenic bone marrow transplantation (or peripheral stem cell transplantation) is performed on about 25 patients annually. The post-bone marrow transplantation long-term survival of standard-risk patients is about 70%, which shows a favorable outcome of treatment. Non-myeloablative transplantation (mini-transplantation), with myelosuppressive action reduced by pretreatment, is applied to elder patients and patients with complications. We also actively perform transplantation from HLA-unmatched related donors and umbilical cord blood transplantation.
In clinical studies, the safety and effectiveness of new therapeutic drugs are intensively examined.
|First visit||8:30 am to 11:00 am|
|Revisit||8:30 am to 11:30 am|
|Revisit with appointment||8:30 am to 3:00 pm|
※First-time visitors to Osaka University Hospital must have a referral from a physician.
Monday to Friday
Saturdays, Sundays, Holidays New Year’s Holidays: Dec. 29 to Jan. 3